Advanced Biomedical Research
Evaluation of the effect of carvedilol in preventing right ventricular dysfunction in breast cancer patients receiving anthracycline
Authors
1 Department of Cardiology, School of Medicine, Research Institute of Taleghani Hospital, Shahid Beheshti University of Medical Science, Tehran, Iran
2 Department of Adult Hematology and Oncology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 Department of Cardiology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4 Department of Adult Hematology and Oncology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5 Department of Adult Hematology and Oncology, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract
Background: Today, it has been shown that it is possible for right ventricular (RV) wall motion abnormalities or RV functional disorders to occur during cancer treatment. Now, considering the effect of carvedilol on beta 1, 2, and alpha receptors and its antioxidant properties, it seems that it can prevent RV abnormalities. Therefore, the aim of this study was to investigate the possible protective effects of carvedilol in preventing RV dysfunction in patients with breast cancer treated with anthracyclines.
Materials and Methods: The present single-blind clinical trial study was performed on 23 patients with breast cancer that 12 of them received only the anthracycline antineoplastic doxorubicin (Adriamycin®) chemotherapy (control group) and 11 patients received carvedilol in addition to anthracycline. To evaluate the effect of carvedilol, patients underwent transthoracic echocardiography before intervention and 2 weeks after the end of treatment with anthracyclines.
Results: The two parameters of RV ejection fraction and RV fractional area change in the carvedilol group with a mean of 66.41% ± 8.10% and 51.85% ± 6.89% were slightly higher than the control group with a mean of 64.58% ± 6.83% and 50.48 ± 5.79%, respectively, which was not statistically significant (P > 0.05). In contrast, RV S wave tissue Doppler imaging (S-TDI) in the control group with a mean of 0.13 ± 0.02 m/s was significantly lower than the carvedilol group with a mean of 0.14 ± 0.02 m/s (P = 0.022).
Conclusion: According to the results of the present study, the effect of using carvedilol as a preservative on improving RV function was seen compared to the control group, although this difference was not statistically significant.
Keywords
| 1. |
Watkins EJ. Overview of breast cancer. J Am Acad PAs 2019;32:13-7.  |
| 2. |
Eden M, Harrison S, Griffin M, Lambe M, Pettersson D, Gavin A, et al. Impact of variation in cancer registration practice on observed international cancer survival differences between International Cancer Benchmarking Partnership (ICBP) jurisdictions. Cancer Epidemiol 2019;58:184-92. |
| 3. |
Farmakis D, Mantzourani M, Filippatos G. Anthracycline-induced cardiomyopathy: Secrets and lies. Eur J Heart Fail 2018;20:907-9. |
| 4. |
Nicolazzi MA, Carnicelli A, Fuorlo M, Scaldaferri A, Masetti R, Landolfi R, et al. Anthracycline and trastuzumab-induced cardiotoxicity in breast cancer. Eur Rev Med Pharmacol Sci 2018;22:2175-85. |
| 5. |
Plana JC, Thavendiranathan P, Bucciarelli-Ducci C, Lancellotti P. Multi-modality imaging in the assessment of cardiovascular toxicity in the cancer patient. JACC Cardiovasc Imaging 2018;11:1173-86. |
| 6. |
Li VW, Liu AP, Wong WH, Ho KK, Yau JP, Cheuk DK, et al. Left and right ventricular systolic and diastolic functional reserves are impaired in anthracycline-treated long-term survivors of childhood cancers. J Am Soc Echocardiogr 2019;32:277-85. |
| 7. |
Grover S, Leong DP, Chakrabarty A, Joerg L, Kotasek D, Cheong K, et al. Left and right ventricular effects of anthracycline and trastuzumab chemotherapy: A prospective study using novel cardiac imaging and biochemical markers. Int J Cardiol 2013;168:5465-7. |
| 8. |
Tanindi A, Demirci U, Tacoy G, Buyukberber S, Alsancak Y, Coskun U, et al. Assessment of right ventricular functions during cancer chemotherapy. Eur J Echocardiogr 2011;12:834-40. |
| 9. |
Chrysohoou C, Antoniou CK, Kotrogiannis I, Metallinos G, Aggelis A, Andreou I, et al. Role of right ventricular systolic function on long-term outcome in patients with newly diagnosed systolic heart failure. Circ J 2011;75:2176-81. |
| 10. |
Guendouz S, Rappeneau S, Nahum J, Dubois-Randé JL, Gueret P, Monin JL, et al. Prognostic significance and normal values of 2D strain to assess right ventricular systolic function in chronic heart failure. Circ J 2012;76:127-36. |
| 11. |
Reymatias J, Villanueva D, Ramiro V, Magno J. P 42Role of statins for the prevention of anthracycline-induced cardiomyopathy: A meta-analysis. Eur Heart J 2020;41:ehz872-036. |
| 12. |
Zamani B, Salehi R, Esfahani A. Protective effect of carvedilol against anthracycline-induced cardiomyopathy on patients with breast cancer and lymphoma. Int J Adv Med 2018;20-5:16. |
| 13. |
Guglin M, Krischer J, Tamura R, Fink A, Bello-Matricaria L, McCaskill-Stevens W, et al. Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer. J Am Coll Cardiol 2019;73:2859-68. |
| 14. |
Calleja A, Poulin F, Khorolsky C, Shariat M, Bedard PL, Amir E, et al. Right ventricular dysfunction in patients experiencing cardiotoxicity during breast cancer therapy. J Oncol 2015;2015:609194. |
| 15. |
Elitok A, Oz F, Cizgici AY, Kilic L, Ciftci R, Sen F, et al. Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: A prospective randomized controlled study with six-month follow-up. Cardiol J 2014;21:509-15. |
| 16. |
Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006;48:2258-62.
|
)